NanoViricides, Inc. (NNVC)
USD 1.5
(0.67%)
USD 1.5
(0.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 8.51 Million USD | -4.78% |
| 2023 | 8.94 Million USD | 10.23% |
| 2022 | 8.11 Million USD | -7.21% |
| 2021 | 8.74 Million USD | 9.35% |
| 2020 | 7.99 Million USD | -7.66% |
| 2019 | 8.65 Million USD | -7.14% |
| 2018 | 9.32 Million USD | -2.87% |
| 2017 | 9.6 Million USD | 8.37% |
| 2016 | 8.85 Million USD | 25.43% |
| 2015 | 7.06 Million USD | -18.51% |
| 2014 | 8.66 Million USD | 31.52% |
| 2013 | 6.59 Million USD | 8.36% |
| 2012 | 6.08 Million USD | -5.41% |
| 2011 | 6.42 Million USD | 30.15% |
| 2010 | 4.93 Million USD | 75.19% |
| 2009 | 2.81 Million USD | 0.99% |
| 2008 | 2.79 Million USD | -9.43% |
| 2007 | 3.08 Million USD | 18.76% |
| 2006 | 2.59 Million USD | 3832.81% |
| 2005 | 66 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.03 Million USD | -44.74% |
| 2024 Q4 | 2.39 Million USD | 39.16% |
| 2024 Q3 | 1.71 Million USD | -13.88% |
| 2024 Q2 | 1.99 Million USD | -1.78% |
| 2023 Q3 | 1.81 Million USD | -1.27% |
| 2023 Q4 | 3.67 Million USD | 103.03% |
| 2023 Q2 | 1.83 Million USD | 13.04% |
| 2023 Q1 | 1.62 Million USD | -9.51% |
| 2023 FY | 8.94 Million USD | 10.23% |
| 2022 Q1 | 2.61 Million USD | 25.94% |
| 2022 FY | 8.11 Million USD | -7.21% |
| 2022 Q4 | 1.79 Million USD | 0.27% |
| 2022 Q2 | 1.92 Million USD | -26.48% |
| 2022 Q3 | 1.78 Million USD | -6.91% |
| 2021 Q2 | 2.29 Million USD | 0.95% |
| 2021 Q3 | 2.1 Million USD | -8.05% |
| 2021 Q1 | 2.27 Million USD | 23.94% |
| 2021 Q4 | 2.07 Million USD | -1.58% |
| 2021 FY | 8.74 Million USD | 9.35% |
| 2020 Q4 | 1.83 Million USD | -27.95% |
| 2020 FY | 7.99 Million USD | -7.66% |
| 2020 Q1 | 1.98 Million USD | -8.33% |
| 2020 Q2 | 1.63 Million USD | -17.78% |
| 2020 Q3 | 2.54 Million USD | 55.55% |
| 2019 Q2 | 2.36 Million USD | 16.19% |
| 2019 Q3 | 2.08 Million USD | -12.08% |
| 2019 FY | 8.65 Million USD | -7.14% |
| 2019 Q4 | 2.16 Million USD | 4.11% |
| 2019 Q1 | 2.03 Million USD | -10.67% |
| 2018 FY | 9.32 Million USD | -2.87% |
| 2018 Q4 | 2.28 Million USD | -5.61% |
| 2018 Q3 | 2.41 Million USD | 1.02% |
| 2018 Q2 | 2.39 Million USD | 7.32% |
| 2018 Q1 | 2.23 Million USD | -0.73% |
| 2017 Q4 | 2.24 Million USD | -14.1% |
| 2017 FY | 9.6 Million USD | 8.37% |
| 2017 Q1 | 2.44 Million USD | -2.22% |
| 2017 Q2 | 2.29 Million USD | -5.85% |
| 2017 Q3 | 2.61 Million USD | 13.84% |
| 2016 Q3 | 2.04 Million USD | -2.01% |
| 2016 Q2 | 2.09 Million USD | -6.06% |
| 2016 FY | 8.85 Million USD | 25.43% |
| 2016 Q4 | 2.49 Million USD | 21.86% |
| 2016 Q1 | 2.22 Million USD | -8.68% |
| 2015 Q4 | 2.43 Million USD | 117.05% |
| 2015 Q2 | 1.81 Million USD | 7.68% |
| 2015 FY | 7.06 Million USD | -18.51% |
| 2015 Q3 | 1.12 Million USD | -38.2% |
| 2015 Q1 | 1.68 Million USD | -55.53% |
| 2014 Q3 | 1.23 Million USD | -29.58% |
| 2014 FY | 8.66 Million USD | 31.52% |
| 2014 Q4 | 3.79 Million USD | 207.6% |
| 2014 Q2 | 1.75 Million USD | -7.27% |
| 2014 Q1 | 1.88 Million USD | 20.88% |
| 2013 Q2 | 1.24 Million USD | -21.83% |
| 2013 Q4 | 1.56 Million USD | -28.67% |
| 2013 Q3 | 2.19 Million USD | 76.15% |
| 2013 FY | 6.59 Million USD | 8.36% |
| 2013 Q1 | 1.59 Million USD | 2.83% |
| 2012 Q1 | 1.14 Million USD | -9.6% |
| 2012 FY | 6.08 Million USD | -5.41% |
| 2012 Q4 | 1.54 Million USD | -25.5% |
| 2012 Q3 | 2.07 Million USD | 55.32% |
| 2012 Q2 | 1.33 Million USD | 17.24% |
| 2011 Q3 | 2.55 Million USD | 70.63% |
| 2011 Q1 | 1.11 Million USD | 29.8% |
| 2011 FY | 6.42 Million USD | 30.15% |
| 2011 Q2 | 1.49 Million USD | 34.87% |
| 2011 Q4 | 1.26 Million USD | -50.68% |
| 2010 Q1 | 732.05 Thousand USD | 16.87% |
| 2010 Q4 | 856.18 Thousand USD | -64.7% |
| 2010 Q3 | 2.42 Million USD | 161.73% |
| 2010 Q2 | 926.56 Thousand USD | 26.57% |
| 2010 FY | 4.93 Million USD | 75.19% |
| 2009 Q2 | 644.5 Thousand USD | -14.84% |
| 2009 Q4 | 626.36 Thousand USD | -20.92% |
| 2009 Q1 | 756.83 Thousand USD | -24.23% |
| 2009 FY | 2.81 Million USD | 0.99% |
| 2009 Q3 | 792.02 Thousand USD | 22.89% |
| 2008 Q3 | 805.31 Thousand USD | 98.75% |
| 2008 Q2 | 405.19 Thousand USD | -30.46% |
| 2008 FY | 2.79 Million USD | -9.43% |
| 2008 Q4 | 998.88 Thousand USD | 24.04% |
| 2008 Q1 | 582.64 Thousand USD | -24.81% |
| 2007 FY | 3.08 Million USD | 18.76% |
| 2007 Q2 | 706.64 Thousand USD | 5.0% |
| 2007 Q3 | 928.36 Thousand USD | 31.38% |
| 2007 Q4 | 774.91 Thousand USD | -16.53% |
| 2007 Q1 | 672.99 Thousand USD | 160.09% |
| 2006 Q4 | -1.11 Million USD | -42.05% |
| 2006 FY | 2.59 Million USD | 3832.81% |
| 2006 Q3 | -788.37 Thousand USD | 14.23% |
| 2006 Q2 | -919.12 Thousand USD | -101.11% |
| 2006 Q1 | -457.03 Thousand USD | 0.0% |
| 2005 FY | 66 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 73.45% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 8.113% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | 26.894% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 83.623% |
| Azitra, Inc. | 8.3 Million USD | -2.574% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | 4.72% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -24.1% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 70.626% |
| CEL-SCI Corporation | 31.47 Million USD | 72.944% |
| iBio, Inc. | 16.85 Million USD | 49.486% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 74.199% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | 57.804% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 65.746% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 38.872% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | 33.973% |
| Oragenics, Inc. | 5.45 Million USD | -56.203% |
| BiomX Inc. | 26.81 Million USD | 68.24% |
| BiomX Inc. | 26.81 Million USD | 68.24% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 73.43% |
| Palatin Technologies, Inc. | 34.67 Million USD | 75.437% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 78.611% |